Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?
- Author(s)
- Wong, AK; Vogrin, S; Klepstad, P; Rubio, J; Le, B; Philip, J; Somogyi, AA;
- Journal Title
- Pharmacogenomics
- Publication Type
- Online publication before print
- Abstract
- AIMS: To examine the associations between CYP2D6 and CYP3A4 polymorphisms, plasma oxycodone and metabolite concentrations, and oxycodone response (dose, pain scores, and adverse effects) in people with pain from advanced cancer. PATIENTS & METHODS: This multi-center prospective cohort study included clinical data, questionnaires (pain and adverse effects), and blood (pharmacokinetics, DNA). Negative binomial regression and logistic regression were used. RESULTS: Within 33 participants, there were no differences in oxycodone response between CYP2D6 intermediate/poor metabolisers compared to normal metabolisers.Higher plasma noroxycodone and noroxycodone/oxycodone concentration ratios had higher odds of uncontrolled average pain (OR 2.44 (95%CI 1.00-5.95), p = 0.05 and OR 10.48 (95%CI 1.42-77.15), p = 0.02, respectively). CONCLUSIONS: There was no observed benefit in CYP2D6 genotyping in oxycodone response, however monitoring noroxycodone and oxymorphone concentrations warrant further examination.
- Keywords
- Opioid; advanced cancer; analgesics; palliative care; pharmacogenetics
- Department(s)
- Palliative Care
- Publisher's Version
- https://doi.org/10.1080/14622416.2024.2430161
- Open Access at Publisher's Site
https://doi.org/10.1080/14622416.2024.2430161- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-01-09 06:35:17
Last Modified: 2025-01-09 06:41:23